Cargando…

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

OBJECTIVE: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, is used to treat chimeric antigen receptor T cell-induced cytokine release syndrome and may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Edmund, Isonaka, Sharon, Yang, Haoshu, Salce, Erin, Rosales, Elisa, Jordan, Stanley C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889004/ https://www.ncbi.nlm.nih.gov/pubmed/33609773 http://dx.doi.org/10.1016/j.ijid.2021.02.057

Ejemplares similares

Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
por: Huang, Edmund, et al.
Publicado: (2020)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
por: Hafez, Wael, et al.
Publicado: (2022)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020)

Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in “non-critically-ill” patients on hemodialysis
por: Castellano, Giuseppe, et al.
Publicado: (2020)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients
por: Fisher, Matthew J., et al.
Publicado: (2021)

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19
por: Zacharias, Harry, et al.
Publicado: (2022)

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
por: Camou, Fabrice, et al.
Publicado: (2022)

Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
por: Szabo, Robert, et al.
Publicado: (2023)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study
por: Mussini, Cristina, et al.
Publicado: (2023)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
por: Aljuhani, Ohoud, et al.
Publicado: (2021)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study
por: Burger, Barrett J., et al.
Publicado: (2023)

Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
por: Zeng, Jia, et al.
Publicado: (2020)

Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study
por: Radulescu, Amanda, et al.
Publicado: (2022)

Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study
por: Jiang, Saiping, et al.
Publicado: (2020)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study
por: Sankar, Keerthana, et al.
Publicado: (2023)

Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Barotrauma, invasive ventilation, and timing of tocilizumab as predictors of mortality along with inflammatory markers and comorbidities in critically ill COVID-19 patients: A retrospective study
por: Zirpe, Kapil, et al.
Publicado: (2021)

Effectiveness of Tocilizumab in Patients with Severe or Critical Lung Involvement in COVID-19: A Retrospective Study
por: Chober, Daniel, et al.
Publicado: (2022)

Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients
por: Cala-García, Juan David, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases
por: ElSeirafi, Mohamed M, et al.
Publicado: (2020)

Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers
por: Atallah, Bassam, et al.
Publicado: (2020)

What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia
por: Miller, Andrew C., et al.
Publicado: (2021)

The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study
por: Korayem, Ghazwa B., et al.
Publicado: (2022)

Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study
por: Hu, Qin, et al.
Publicado: (2021)

Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
por: Al-Qaaneh, Ayman M., et al.
Publicado: (2022)

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
por: Petrak, Russell M., et al.
Publicado: (2021)

Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis
por: Ignatius, Elisa H, et al.
Publicado: (2020)

Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
por: Rashad, Alaa, et al.
Publicado: (2021)

Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome
por: Wu, Kuo-Lun, et al.
Publicado: (2022)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
por: Xu, Yonghao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nfc08t353aooffq91oosk2kvfi